Overview

An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Status:
Completed

Trial end date:
2014-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the objective response rate of lenvatinib in previously treated participants with American Joint Committee on Cancer (AJCC) unresectable Stage III or Stage IV melanoma and disease progression.

Phase:

Phase 2

Details

Lead Sponsor:

Eisai Inc.

Treatments:

Lenvatinib